GLPG Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €25.28 |
52 Week High | €40.26 |
52 Week Low | €24.90 |
Beta | 0.038 |
1 Month Change | -4.89% |
3 Month Change | -21.73% |
1 Year Change | -34.34% |
3 Year Change | -58.52% |
5 Year Change | -75.46% |
Change since IPO | 58.00% |
Recent News & Updates
Recent updates
Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be
Apr 19Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business
Jan 03Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S
Jul 18€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results
May 06Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation
Mar 29Shareholder Returns
GLPG | NL Biotechs | NL Market | |
---|---|---|---|
7D | 0.08% | 0.1% | -1.2% |
1Y | -34.3% | -11.7% | 16.7% |
Return vs Industry: GLPG underperformed the Dutch Biotechs industry which returned -11.7% over the past year.
Return vs Market: GLPG underperformed the Dutch Market which returned 16.7% over the past year.
Price Volatility
GLPG volatility | |
---|---|
GLPG Average Weekly Movement | 2.3% |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 4.0% |
10% most volatile stocks in NL Market | 6.8% |
10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: GLPG's share price has been volatile over the past 3 months.
Volatility Over Time: GLPG's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
GLPG fundamental statistics | |
---|---|
Market cap | €1.67b |
Earnings (TTM) | €30.71m |
Revenue (TTM) | €243.58m |
54.2x
P/E Ratio6.8x
P/S RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLPG income statement (TTM) | |
---|---|
Revenue | €243.58m |
Cost of Revenue | €262.90m |
Gross Profit | -€19.31m |
Other Expenses | -€50.02m |
Earnings | €30.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 0.47 |
Gross Margin | -7.93% |
Net Profit Margin | 12.61% |
Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison